Moxifloxacino Krka

Moxifloxacin, the active ingredient in Moxifloxacino Krka, is a fluoroquinolone antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, particularly respiratory and skin infections, in adult patients when prescribed by a qualified healthcare professional.

GNH USA supplies Moxifloxacino Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacino Krka is a fluoroquinolone antibiotic used to treat bacterial infections affecting the respiratory tract and skin. - Community‑acquired pneumonia: eradicates susceptible pathogens causing lower‑respiratory infection. - Acute bacterial sinusitis: clears infection of the paranasal sinuses. - Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load during flare‑ups. - Skin and soft‑tissue infections: eliminates susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacino Krka may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or loss of function. - QT interval prolongation: potential cardiac arrhythmia. - Severe allergic reaction: anaphylaxis with swelling, breathing difficulty. - Clostridioides difficile infection: severe colitis after antibiotic use. - Hepatic toxicity: elevated liver enzymes or jaundice. - Peripheral neuropathy: tingling or numbness in extremities.

Before prescribing Moxifloxacino Krka, clinicians should consider patient‑specific factors and safety measures. - Assess renal and hepatic function: adjust use if organ impairment is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Caution with QT‑prolonging conditions: monitor cardiac rhythm in at‑risk patients. - Use carefully in elderly: higher incidence of tendon and CNS effects. - Avoid concurrent fluoroquinolone therapy: increased risk of toxicity. - Store at below 25°C: keep in original packaging, protect from moisture.

Moxifloxacino Krka can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of moxifloxacin. - QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): increase risk of cardiac arrhythmia. - Warfarin: may enhance anticoagulant effect, raising INR. - Theophylline: can raise plasma theophylline levels, causing toxicity. - NSAIDs: heightened risk of central nervous system stimulation.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (cimetidine): may increase moxifloxacin concentrations. - CYP3A4 inducers (rifampin): may lower drug exposure. - Corticosteroids: combined use raises tendon‑rupture risk. - Diabetic agents: potential for enhanced hypoglycaemia. - Oral contraceptives: possible reduction in contraceptive efficacy.